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Abstract
Objective—To develop a novel diagnostic algorithm for Lyme disease among children with
facial palsy by integrating public health surveillance data with traditional clinical predictors.
Design—Retrospective cohort study.
Setting—Children’s Hospital Boston emergency department,1995–2007
Patients—264 children under age 20 years presenting with peripheral facial palsy who were
evaluated for Lyme disease
Main outcome measures—Multivariate regression was used to identify independent clinical
and epidemiologic predictors of Lyme facial palsy.
Results—65% of children from high-risk counties during Lyme season tested positive, compared
to 5% of children without geographic or seasonal risk factors present. Among patients with both
seasonal and geographic risk factors, 80% with one clinical risk factor (fever or headache) and
100% with two clinical factors had Lyme. Factors independently associated with Lyme facial
palsy were presentation from June-November (odds ratio 25, 95% CI 8.3–113), residence in a
county where the most recent three year average Lyme incidence exceeded 4 cases/100,000 (18,
6.5–69), fever (3.9, 1.5–11), and headache (2.7, 1.3–5.8). Clinical experts correctly treated 68/94
(72%) patients with Lyme facial palsy, but a tool incorporating geographical and seasonal risk
identified all 94 cases.
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Conclusions—Most clinicians intuitively integrate geographic information into Lyme disease
management, but we demonstrate quantitatively how formal use of geographically-based
incidence in a clinical algorithm improves diagnostic accuracy. These findings demonstrate
potential for improved outcomes from investments in health information technology that foster
bidirectional communication between public health and clinical settings.
Keywords
Lyme disease; clinical decision support systems; tick-borne diseases; epidemiologic methods;
public health informatics
Introduction
Background
When the possible causes of a patient’s condition vary geographically, knowledge about
local scale disease incidence could help steer clinicians towards the most likely diagnosis.
Children with peripheral facial palsy pose a diagnostic challenge, because optimal
management at the point of care requires correctly identifying the etiology for the palsy.
Rapid point-of-care testing for Lyme disease is not available, so diagnostic test results, if
ordered, often are not known for several days, leaving clinicians to choose a treatment
strategy without confirmatory serology. Over-diagnosis of Lyme is associated with
excessive antibiotic use, and under-diagnosis with progression to more complications. At
one time otitis media accounted for most identifiable cases of facial palsy in children.1
Infections with Borrelia burgdorferi have increased over the past several decades, so Lyme
disease, the most frequently reported vector-borne disease in the United States, now
accounts for a substantial proportion of cases in endemic areas.2–4 Antivirals and
corticosteroids may be helpful in adults with facial palsy.5 For children with Lyme facial
palsy, early initiation of appropriate antibiotics is the optimal strategy, and according to the
American Academy of Pediatrics Red Book Committee on Infectious Diseases, steroids
should not be given.6
Importance
Prediction rules traditionally factor in historical elements, physical exam findings and
sometimes seasonality to identify the correct cause of the facial palsy, but to date, none of
the rules have incorporated residential location as a predictor.7 Epidemiological context– the
recent regional incidence of a disease, often calculable from clinical or public health datasets
– may be an important predictor, in the absence of timely diagnostic data.8, 9 Even within
endemic areas, Lyme disease incidence varies by location and season, in part because the
irregular local and regional distribution of ticks depends on landscape ecology, and micro-
and macrometerologic conditions.10, 11 While prior studies have considered ecologic and
entomologic risk to generate community-level Lyme prevention recommendations and
vaccination strategies,12–15 this analytic approach has not yet extended to manipulating
formal management algorithms for symptomatic patients by combining geographic risk with
clinical features.
Goals of this Investigation
To optimize management of peripheral facial palsy in children, clinical decision models
would incorporate local epidemiological risk to differentiate Lyme disease from other
etiologies. Taking a novel approach, integrating epidemiological information about location
and season with traditional clinical variables, we sought to create a model to improve
diagnostic accuracy and management of children with peripheral facial nerve palsy. We
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hypothesize that quantitative use of the patient’s geographic risk of Lyme disease would
improve the accuracy of diagnosis.
Methods
Design, setting and subjects
Our sample was a retrospective cohort of children under 20 years old presenting to the
emergency department (ED) of Children’s Hospital Boston, a large, urban tertiary care
hospital, from 1995–2007. The study site ED volume exceeds 50,000 patients annually. We
only included children residing in Massachusetts.
Selection of Participants
ED visits of patients with peripheral facial nerve palsy were identified by a computer-
assisted key word screening tool and regular expression matching from all ED visits at the
study site during the study period.16 We included only those children with facial palsy who
were evaluated for Lyme disease (either by obtaining Lyme serology or by the presence of
erythema migrans rash). Patients were excluded from the analysis if they had any of the
following characteristics causing facial palsy: congenital facial palsy, known central nervous
system malignancy, known history of herpes simplex virus, surgery near the facial nerve
within one week of presentation, or Todd’s or more generalized paralysis, including
hemiparesis.
Case definition
A child was defined to have Lyme disease according to the CDC definition: presence of
erythema migrans lesion or serologic evidence of infection with Borrelia burgdorferi via the
two-tiered testing strategy.17 Children were only classified positive in our study if the
Western blot was positive using the laboratory reference standards. Offsite commercial
laboratory personnel (ARUP – Salt Lake City; Immugen – Norwood, MA) performed
serologic testing for B burgdorferi. Patients with positive enzyme-linked immunosorbent
assay and negative Western blot or no Western blot performed were not considered positive
for Lyme disease.18
Predictor variables and data collection
Demographics, onset and duration of symptoms, clinical features, laboratory data and
treatment data were collected for each patient via comprehensive chart review by two
investigators specializing in pediatric emergency medicine (LEN, ADT). Signs and
symptoms included headache, fever, muscle aches, joint pains, rash and potential exposures
such as tick bites. Laboratory data were reviewed for Lyme test results. Treatment data
included type and duration of treatment with antibiotics or steroids. To assess inter-rater
reliability, an independent abstractor specializing in pediatric emergency medicine (AMF)
reviewed eight percent of charts chosen at random.19, 20 Candidate predictors with kappa
statistics with a lower limit of 95% confidence interval of > 0.4 were considered for the
multivariate analyses.21 Visit date and county of residence for each patient were obtained
from the chart review. County-level annual Lyme incidence was calculated from available
public health surveillance data from the Massachusetts Department of Public Health Office
of Integrated Surveillance Informatics Services.2, 22–24 These data were used to calculate the
average Lyme incidence over the prior three years in the home county for each patient. For
example, for a patient presenting from Essex County in 2004, the incidence in that county
was averaged from 2001–2003.
Fine et al. Page 3
Arch Pediatr Adolesc Med. Author manuscript; available in PMC 2013 May 03.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Building the decision models
Three decision models were built with clinical and epidemiological variables: 1) Clinical
model – candidate predictors included traditional elements – data on demographics, history
and physical exam; 2) Epidemiologic model – candidate predictors included the timing of
presentation (month or season) and the incidence variables associated with the county of
residence; and 3) Contextualized model – variables not included in the prior two models still
qualified for inclusion into this model, which combined clinical and epidemiological
predictors.
Univariate and multivariate analysis
Univariate and multivariate analytic techniques were used to identify predictors of Lyme
disease among patients with peripheral facial palsy. Significance of association of
categorical variables with Lyme disease was tested by Chi square. Continuous variables (i.e.
average county incidence of Lyme disease in prior 3 years) were dichotomized at categorical
cutoffs (e.g. average incidence > 20 cases/100,000 people). Recursive partitioning was used
to identify thresholds for testing univariate and multivariate associations.
In the multivariate analyses, candidate variables were entered into a backward stepwise
logistic regression to identify independent predictors of patients with Lyme disease. P value
cutoffs for entry and departure for the multivariate regression models were 0.25 and 0.10,
respectively. The final models contained variables where p<0.05.
Several seasonal variables were considered independently for entry into the models. A range
of cutoffs was considered to define patients who presented in “Lyme season,” (June–
October, May–December, June–November), because “Lyme season” varies by geography,
climate, suitability for tick populations and annual trends.25 For the spatial variables, the
annual county Lyme disease incidence in each of the prior three years and the overall three
year average incidence were considered as independent predictors. Recursive partitioning
was used to identify a cutoff for the three year average Lyme incidence in the county of
residence, and this cutoff was considered as an independent candidate predictor. Final
models underwent bootstrap validation. Predictors selected in over 50% of 1000 bootstrap
analyses were retained in the final models.26–28
Methods of measurement of model performance
Sensitivity, specificity, positive and negative predictive values, and area under the ROC
curve, were used to compare performances of the models. Actual management by pediatric
emergency medicine experts was compared to management guided by the decision models.
Correct management of Lyme facial palsy was defined as use of a correct antibiotic for a
correct duration and omission of corticosteroids and antivirals, as defined by the expert
panel in the American Academy of Pediatrics Red Book Committee on Infectious Diseases.6
The Committee on Clinical Investigation of Children’s Hospital Boston approved the study.
Results
From 1995–2007, there were 609,671 visits to this emergency department for patients under
age 20 years. Table 1 displays the characteristics of the 264 patients (0.04% of all ED visits)
who presented with peripheral facial palsy, were evaluated for Lyme disease and met study
criteria. Patients evaluated for Lyme disease (n=264) were similar to those not evaluated for
Lyme disease (n=156) with respect to age, gender and presence of fever and were more
likely to have headache (28% vs 12 %, p=0.001) and present during Lyme season (49% vs
31%, p=0.001). The patients came from the nine Eastern-most of the 14 counties in
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Massachusetts. Figure 1 shows county-level average incidence of Lyme disease for
Massachusetts over one three year period of the study.
Development of clinical decision model
Univariate analysis—Patients with Lyme were more likely to be male, have a history of
fever, headache, systemic symptoms like myalgias and arthritis and no history of trauma to
the face or head (Table 1). There were no significant differences between those with and
without Lyme for age, neck pain, or otitis media. Exposure to tick bite was not captured in
the vast majority of charts, and so could not be considered for the analyses.
Multivariate analysis—In the clinical model, headache (OR 4.4, 95% CI 2.2–7.5) was the
most significant predictor of Lyme facial palsy, followed by fever (3.3, 1.6–7.1) (Table 2).
Presence of either of these two predictors identified children with Lyme with 60%
sensitivity, 79% specificity, and area under the ROC curve (AUC) of 0.71. The PPV was
61% and the NPV was 79%.
Development of models incorporating epidemiological context: Selection of seasonal
variable
Univariate analyses were conducted using a range of cutoffs to define Lyme season.
Recursive partitioning identified candidate cutoffs for Lyme season. Patients with Lyme
disease were more likely to present during any of the defined Lyme seasons. The Lyme
season defined as “June–November” showed a stronger association for Lyme than “June–
October” or “May–December” so for further analyses, June–November was used as Lyme
season.
Selection of spatial variable—Univariate analysis was used to examine associations
between Lyme disease and Lyme incidence rates in the patient’s home county. Recursive
partitioning identified cutoffs to classify 3 year county average incidences as high or low
risk. The low risk cutoff occurred when the average three year Lyme incidence for a county
was less than four cases/100,000 people. Annual incidence and three year average incidence
were associated with Lyme disease, but the cutoff incidence of >4 cases/100,000 people was
the strongest spatial predictor, and was retained as the spatial predictor for the rest of the
analyses.
The best epidemiological model contained two variables—Lyme season (June–November)
and high-risk home location (three year average county-specific Lyme incidence > 4 cases/
100,000 people). Lyme season (OR 25, 95% CI 8.6–107) and high-risk home location (20,
7.4–68) were both very strong predictors with odds ratios above 20 (Table 2). The AUC for
this model was 0.84.
The contextualized model considering all clinical and epidemiologic variables regardless of
whether they entered into the previous models contained four variables: fever (OR 3.9, 95%
CI 1.5–11), headache (OR 2.7, 1.3–5.8), Lyme season (OR 25, 8.3–113) and high-risk home
location (OR 18, 6.5–69) (Table 2). The AUC for this model was 0.89. This model was
100% sensitive and 24% specific with a PPV of 42% and NPV of 100%.
Validation
All predictors from the multivariate analyses were validated by the bootstrap method and
retained in the final models. High-risk location was selected in over 99%, Lyme season in
over 97%, fever in over 81% and headache in over 77% of 1000 bootstrap analyses.
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Measurement of model performance
Adding epidemiologic factors (seasonal and spatial variables) to the clinical model improved
the AUC from 0.71 to 0.89, whereas adding clinical factors to the epidemiological model
improved the AUC more modestly, from 0.84 to 0.89. Figure 2 illustrates the risk of Lyme
facial palsy based on the presence of high-risk predictors. Of the 264 patients in the study,
134 presented from high-risk locations during Lyme season, and 87 (65%) had Lyme. In
contrast, 7/130 (5%) patients who presented without both high risk location and season were
positive for Lyme. A total of 69 patients presented from high-risk locations during Lyme
season without either clinical predictor (fever or headache), and 35 (51%) of these patients
had Lyme. Of the 65 patients who presented with fever, headache or both, in conjunction
with high-risk location and Lyme season, 52 (80%) had Lyme. The combinations that
included both season and location identified 87/94 (93%) of Lyme cases. Finally, none of
the 42 patients without any of the four identified risk factors had Lyme disease.
Comparing clinician performance with decision models
We compared the proportion of children with facial palsy empirically treated with the
appropriate medications by attending physicians in the pediatric emergency department with
hypothetical outcomes generated by the three models. These physicians treated 68/94 (72%)
Lyme disease patients with the correct type of antibiotics and without steroids or antivirals.
The epidemiologic and contextualized models did not miss any cases of Lyme disease.
Discussion
To date, clinical decision rules have relied on clinical factors and to a much lesser extent,
seasonality. In the case of Lyme disease, clinicians may informally consider exposure and
location when determining the cause of facial palsy, but there are currently no mechanisms
that formally facilitate integration of this important contextual information. To the extent
that clinicians use contextual epidemiological information to help guide decision making,
they tend to use it informally and to rely on personal or pooled collective experiences to
reason about diagnosis, testing and treatment.29–31 While most clinicians certainly often
intuitively integrate geographic information into their diagnostic workup for Lyme disease,
we show that a quantitative, formal integration of geographically based incidence improves
diagnosis and treatment.
Within endemic regions of the United States, selected states have higher Lyme rates, and
within those states, there is significant variation by county. Our findings support a general
approach of estimating clinical risk of disease at the point of care, accounting for recent
spatial incidence. This approach emphasizes applying epidemiologic context to the clinical
decision making process rather than relying solely on history, physical exam, heuristics and
preliminary diagnostic test results.9, 32, 33 Improved collaboration between public health
departments and clinicians, the maturation of electronic health records, and advances in
disease surveillance and automated reporting now increase the feasibility of delivering
readily available and easily computed relevant public health information to clinicians at the
point of care.34–36
Previously, we showed that epidemiological information about meningitis from a single
hospital provides valuable epidemiological context and enhances a decision model for
distinguishing aseptic from bacterial meningitis.8 We have also illustrated how an external
public health surveillance source improves a clinical decision model, by incorporating state-
wide “epidemiological context.”37 Now, for the first time, we show how spatial incidence
data improves the ability of a model to identify cases of an infectious disease. In our
analyses, epidemiological context variables like season and home location were stronger
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than any clinical predictor in identifying patients with Lyme facial palsy, building upon a
previous clinical model that did not consider home location.7 Epidemiological context was
especially powerful when combined with clinical factors. These findings stress the
importance of “situational awareness” in clinical settings. Understanding the
epidemiological context in which a patient presents may provide vital information about the
etiology of the patient’s problem, but currently, valuable spatiotemporal data are not
formally processed, considered, utilized or integrated into the clinical decision-making
process.
Clinical and public health datasets offer synergistic information that can be leveraged to
generate and refine clinical decision algorithms. Public health data have not typically
contributed information to generate decision models because while they contain records
about those with confirmed disease, they provide little if any information about those
without the disease of interest. This creates unique challenges to the integration of public
health data into decision models, which rely on rich information about patients both with
and without the disease.38, 39 To capitalize on the use of public health data, we relied on
incidence rates to develop and refine a decision model for Lyme disease, a condition with
significant morbidity and of increasing public health importance.
Limitations
External validation should be considered prior to integration into a clinical setting, as the
performance of predictive indices may deteriorate in subsequent validation studies.40 Our
study was confined to Massachusetts, a state endemic for Lyme disease. Specific definitions
of thresholds may vary when more geographically diverse data are considered. Second, this
study occurred at a single ED. However, this site provides care for 75% of the children who
live in and around this large metropolitan area. Third, residential county was taken from ED
registration data, which may not accurately reflect home location for patients with multiple
home addresses. This residential location also does not reflect exposures during travel, but
does represent the best available exposure data. More accurate information about patient
home location would probably strengthen the accuracy of a model incorporating residential
location. Fourth, due to the retrospective nature of the study, we only were able to include
patients in whom a diagnosis of Lyme disease was considered, and not patients with subtle
presentations where the clinician did not consider Lyme as an etiology for facial palsy.
Lyme incidence data are county-level, and do not account for variation within county, so
future investigations using larger data sets, might provide adequate power to obtain finer
spatial resolution. For example, availability of zip code level incidence data might provide
more refined risk stratification. Future studies could also incorporate surrogate markers for
local disease incidence, such as vector surveys and canine serosurveys. Last, compliance
with mandatory reporting requirements by laboratories and clinicians is highly variable41, so
underreporting of Lyme disease is a limitation.
Conclusions
This study emphasizes the benefit of integrating epidemiologic context into a clinical
decision model. We found that, contextual spatial and seasonal epidemiologic factors
dominated clinical factors in distinguishing Lyme disease from other causes of pediatric
peripheral facial palsy. This study adds to a growing body of evidence that clinical decision
support systems can be improved by introducing “epidemiologic context” variables into
algorithms. Public health and clinical information simultaneously presented to a decision
support application improves diagnostic accuracy. An important goal of national efforts to
promote health information technology should be to foster electronic bidirectional
communication of data and messaging between public health and clinical sites.
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Figure 1.
This map of Massachusetts shows the average incidence (# of cases per 100,000 people) of
Lyme disease by county over a three year period. It displays the data used to measure the
risk associated with home location for patients who presented with facial palsy to the
pediatric emergency department in the year following this three year interval.
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Figure 2.
Presence of high-risk predictors among those with and without Lyme facial palsy
Presence of epidemiological and clinical risk factors and rate of Lyme disease among 264
children who presented with peripheral facial palsy. This diagram splits patients by the
presence of two, one, or no epidemiological risk factors. Patients presenting from high-risk
locations during Lyme season are displayed on the top, further stratified by the presence of
clinical risk factors. Patients with only one epidemiological risk factor present are grouped
in the middle branch of the tree, and are also further stratified by the presence of clinical risk
factors. Patients without either epidemiological risk factor are shown at the bottom of the
tree.
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Table 1
Characteristics of the 264 Patients with Peripheral Facial Palsy
Characteristic Lyme disease absent (n=170) Lyme disease present (n=94) P value
N (%) N (%)
Male gender 75 (44%) 65 (69%) <0.0001
Mean age (years) (median/IQ range) 10.9 (12,7–15) 9.8 (9.5,7–13) 0.08
Lyme season (present June–November) 87 (51%) 91 (97%) <0.0001
Trauma to face/head 12 (7.1) 1 (1.1) 0.036
Otitis media 11 (6.5) 2 (2.1) 0.15
Fever 14 (8.2) 30 (32) <0.0001
Headache 28 (16) 48 (51) <0.0001
Systemic symptoms/myalgias 12 (7.1) 19 (20) 0.0024
Neck pain 1 (0.6) 2 (2.1) 0.29
Arthritis 1 (0.6) 5(5.3) 0.023
Prior three year mean Lyme incidence (median, IQ range)in
county of residence
11 (3.9, 2.9–17) (per 100,000) 19 (20, 13–24) (per 100,000) <0.0001
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Table 2
Multivariate Analyses
High-risk predictors for Lyme disease among patients with facial palsy for the three models.
Characteristic Odds Ratio 95% Confidence Intervals P value
Clinical model (AUC* = 0.71)
Headache 4.4 2.2 to 7.5 <0.0001
Fever 3.3 1.6 to 7.1 0.0017
Epidemiological model (AUC=0.84)
Lyme season** 25 8.6 to 107 <0.0001
High-risk location*** 20 7.4 to 68 <0.0001
Contextualized Model (AUC=0.89)
Fever 3.9 1.5 to 11 0.0071
Headache 2.7 1.3 to 5.8 0.0095
Lyme season** 25 8.3 to 113 <0.0001
High-risk location*** 18 6.5 to 69 <0.0001
*AUC: Area under Receiver Operator Characteristic Curve
**
Lyme season = June to November
***
High risk location: 3 year average Lyme incidence > 4/100,000 in county of residence.
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